EP2291179A2 - Nouvelles compositions dépigmentantes anhydre comprenant un dérivé phénolique solubilisé - Google Patents

Nouvelles compositions dépigmentantes anhydre comprenant un dérivé phénolique solubilisé

Info

Publication number
EP2291179A2
EP2291179A2 EP09769518A EP09769518A EP2291179A2 EP 2291179 A2 EP2291179 A2 EP 2291179A2 EP 09769518 A EP09769518 A EP 09769518A EP 09769518 A EP09769518 A EP 09769518A EP 2291179 A2 EP2291179 A2 EP 2291179A2
Authority
EP
European Patent Office
Prior art keywords
composition according
composition
hydroquinone
derivatives
phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09769518A
Other languages
German (de)
English (en)
French (fr)
Inventor
Claire Mallard
Karine Nadau-Fourcade
Fabienne Louis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Publication of EP2291179A2 publication Critical patent/EP2291179A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A61K2800/31—Anhydrous

Definitions

  • New anhydrous depigmenting compositions comprising a solubilized phenolic derivative
  • the present invention relates to a new cosmetic or pharmaceutical depigmenting composition characterized in that it comprises, as a pharmaceutical active ingredient, a phenolic derivative solubilized in the fatty phase for topical application, and to its preparation process and its use in dermatology.
  • phenolic derivatives and more particularly polyphenols remain, for decades, among the most effective assets.
  • the therapeutic use of these agents results from the observation of skin depigmentation in workers in the rubber industry where some of these products are used as antioxidants. Since then, numerous studies have only confirmed their efficacy alone or in combination with other depigmenting agents [Jorge L. Sanchez, M.D. and Miguel Vazquez, M. International Journal of Dermatology Jan.-Feb 1982 vol 21 p55 58]. They thus appear as virtually inescapable assets in the treatment of hyperpigmentation and are therefore present in many commercial products.
  • hydroquinone is the most used pharmaceutical active ingredients.
  • Hydroquinone has been the subject of various patent applications, and in particular US Pat. No. 3,856,934, in which hydroquinone is in combination with retinoic acid and a corticosteroid as depigmenting composition.
  • Rucinol or lucinol, or 4-butyl-resorcinol is a phenol derivative pharmaceutical active agent, polyphenol type marketed as agent for lightening brown spots related to pigmentation disorders (product Iklen ®).
  • hydroquinone, rucinol or their salts or derivatives are solubilized in the aqueous phase of the preparation.
  • phenol derivatives such as hydroquinone or rucinol
  • phenol derivatives are often exposed to heat during the embodiment phase of the composition, especially in conventional emulsions, a phenomenon that initiates and accelerates the phenomenon. browning.
  • reducing agents are used to combat this degradation, in particular sulfites, which are almost unavoidable.
  • these antioxidants have a number of disadvantages such as skin irritation problems, odor in the formulations or destabilization of the formula related to a loss of viscosity.
  • Hydroquinone because of its high concentration of irritating effect can cause post-inflammatory hypermelanosis and ochronosis phenomena.
  • hydroquinone Treatment with hydroquinone may be accompanied by irritation that may lead to post-inflammatory hyperpigmentation.
  • the incidence of irritation depends on the concentration of hydroquinone. The latter is quite important for the 10% concentrations and strongly decreases for the 5% virtually zero at 2% concentration ["Depigmenting Chemicals" JP. Ortonne Ann. Dermatol. Venerol. 1986, 13: 733-736].
  • the galenic chosen can therefore play a leading role in minimizing these effects.
  • the phenol derivatives and in particular hydroquinone or rucinol in solubilized form should be formulated in a formulation that makes it possible to avoid the presence of sulphites and to limit the use of at least antioxidants.
  • hydroquinone is generally solubilized in alcoholic or glycolic solvents before being incorporated in the remainder of the anhydrous preparation.
  • compositions comprising hydroquinone and an anhydrous base consisting of an anhydrous solvent and a high molecular weight silicone vehicle.
  • the hydroquinone is in this case solubilized in a solvent preferably selected from the group of monohydric alcohols (such as isopropanol), dihydric alcohols (such as glycols), trihydric alcohols (such as glycerol).
  • a solvent preferably selected from the group of monohydric alcohols (such as isopropanol), dihydric alcohols (such as glycols), trihydric alcohols (such as glycerol).
  • These compositions do not contain sulphites but require lipophilic antioxidants in a fairly large amount. Indeed, the hydroquinone in such a medium undergoes any degradation, less marked than in water but sufficiently important to require the presence of lipophilic antioxidants in proportions of up to 0.75% by weight relative to the weight of the composition.
  • One of the aims of the present invention is here to solubilize the phenolic derivative in an oily solvent in which the active agent is both soluble and stable and in which it is then possible to envisage the incorporation of the active ingredient into manufacturing processes that require heating steps without having an impact on the stability of the asset.
  • Another object of the present invention is to provide an anhydrous pharmaceutical composition intended for topical application having a prolonged stability, allowing optimized release of the active agent while being very well tolerated.
  • the present invention thus relates to a novel anhydrous stable composition, in particular for topical application, comprising a phenol derivative of the polyphenol type solubilized in the fatty phase.
  • composition according to the invention by virtue of its anhydrous composition, guarantees both excellent stability and harmlessness of the composition.
  • the object of the present invention is an anhydrous pharmaceutical composition
  • a phenolic derivative-type pharmacological active agent and in particular of the polyphenol type, and characterized in that the said phenolic derivative is solubilized in the fatty phase.
  • phenolic derivative-type pharmaceutical active agent By phenolic derivative-type pharmaceutical active agent according to the invention, mention may be made, without limitation, of polyphenols and more particularly hydroquinone, rucinol or lucinol and their salts, 4-hydroxyanisol, hydroquinone monoethyl ether and monobenzyl ether. hydroquinone. Preferably, hydroquinone, or rucinol and its salts are used.
  • the term "rucinol salt” is intended especially to mean salts formed with a pharmaceutically acceptable base, in particular a mineral base such as sodium hydroxide, potassium hydroxide and ammonia, or an organic base such as lysine, arginine or N-methyl.
  • the amount of phenol derivative is from 0.01 to 10% by weight relative to the total weight of the composition, preferably from 0.05 to 6% by weight and more particularly from 0.1 to 5% by weight.
  • anhydrous composition is meant a composition comprising a quantity of water less than or equal to 5% by weight relative to the total weight of the composition. In a preferred embodiment according to the invention the composition does not contain water.
  • stable composition is meant a chemically and physically stable composition.
  • chemical stability is meant in particular that no degradation of the active is observed over time and at temperatures of between 4 and 40 ° C.
  • physical stability it is meant in particular that the compositions do not exhibit any changes in macroscopic appearance in particular of color or microscopic appearance, without evolution of viscosity over time and at temperatures between 4 and 40 ° C.
  • ambient temperature means a temperature between 20 and 30 ° C.
  • compositions according to the invention make it possible to avoid the instability of the phenol derivative, in particular its oxidation in an aqueous medium.
  • the use of sulphites essential for the stabilization of hydroquinone or rucinol in aqueous medium is no longer necessary.
  • the compositions according to the invention make it possible not to use sulphites and to reduce the amount of antioxidants conventionally used in compositions containing water.
  • the composition does not contain sulphites and contains an amount of antioxidants strictly less than 0.3% by weight relative to the total weight of the composition.
  • the antioxidants that can be used according to the invention are preferably antioxidants such as vitamin E and its derivatives, such as DL alpha Tocopherol or Roche tocopherol acetate; vitamin C and its derivatives, such as Roche's Ascorbyl Palmitate, butylhydroxytoluene sold under the name Nipanox BHT by Clariant.
  • the composition according to the invention does not contain an antioxidant.
  • the composition according to the invention does not comprise a preservative.
  • the composition according to the invention by its anhydrous nature and given the choice of ingredients is a self-protected formula.
  • self-protected according to the invention means a formula that does not require the presence of preservative to ensure its bacteriological cleanliness. The absence of preservative makes it possible to guarantee the absence of known intolerance or sensitization phenomena which could be induced by the preservatives.
  • composition according to the invention comprises at least one subsequent fatty phase of the active ingredient, or a subsequent oily phase of the active agent, making it possible to obtain the desired solubility and stability qualities of the active ingredient.
  • oily solvents of the active it is understood in particular:
  • oils such as castor oil, sweet almond oil sold by Sictia or sesame oil sold by CPF; silicone oils such as cyclomethicone sold under the name ST-Cyclomethicone 5NF by Dow Corning or Dimethicone sold under the name Q7 9120 silicon fluid by Dow Corning;
  • mineral oils such as Marcol 152 or Primol 352 sold by Esso;
  • triglycerides such as Caprylic / Caprique Triglycerides sold under the name Miglyol 812 N by IMCD, or derivatives such as PEG-8 caprylic capric triglycerides sold under the name Labrasol by Gattefossé;
  • esters such as the Octyl Dodecyl Myristate sold under the name MOD by Gattefossé, the C12-C15 alkyl benzoate sold under the name Tegosoft TN by Goldschmit or the cetearyl isononanoate sold under the name Cetiol SN PH by Cognis or else diisopropyl adipate sold under the name Crodamol DA by Croda; Guerbet alcohols such as octyldodecanol sold under the name Eutanol G by Cognis;
  • PPG-15 stearyl ether or any other ether or derivative, diisopropyl adipate or any other ester or derivative or triglycerides, such as capric capric triglycerides or their derivatives or a mixture are preferably chosen as oily solvents. of these compounds.
  • the composition according to the invention more particularly comprises a mixture of solvents.
  • the solvent mixture will consist of at most 15% (by weight relative to the total weight of the composition) of ethers-derived solvent. In the composition according to the invention, this amount of solvent, combined with the other new solvents present, is sufficient to solubilize the desired concentrations of active ingredients and to obtain stable preparations.
  • the following oily phase of the active agent comprises at least one oily solvent of the active agent and / or a lipophilic surfactant.
  • lipophilic surfactant is meant more particularly
  • Polyoxyethylenated castor oil derivatives for example PEG-35 castor oil marketed in particular under the name Cremophor EL by BASF; Polyoxyethylenated derivatives of fatty acid esters such as PEG-8 caprylic capric triglycerides marketed under the name of LABRASOL
  • the composition comprises at least one following oil phase of the active ingredient. It may also comprise at least one non-following fat phase of the asset.
  • the composition comprises a following oil phase of the active and a non-following fat phase of the active; alternatively, preferably, the composition comprises only a following oil phase of the active.
  • the amount of subsequent fat phase in the composition according to the invention is generally between 5% and 99%, preferably from 10 to 98% by weight relative to the total weight of the composition.
  • compositions according to the invention do not contain alcoholic or glycolic solvents.
  • composition according to the invention may furthermore comprise at least one gelling agent or lipophilic thickener according to the desired viscosity. Indeed, these compounds are used in the present invention as "viscosity adjusters”.
  • lipophilic thickeners or gelling agents are meant compounds, especially chosen from waxes, hydrogenated oils and fatty acid esters.
  • wax is generally meant a lipophilic compound, solid at room temperature (25 ° C.), with a reversible solid / liquid state change, having a melting point of greater than or equal to 30 ° C. and up to at 200 ° C. and especially up to 120 ° C.
  • useful waxes mention may be made of carnauba wax, microcrystalline waxes, beeswax, marketed under the name White Cerabeil by Barlocher, glyceryl behenate, its derivatives such as glyceryl monobhenenate, glyceryl dibehenate, tribehenin or a mixture thereof, such as the product marketed under the name Compritol 888 by Gattefossé or candelilla wax.
  • Hydrogenated oil is understood to mean the oils obtained by catalytic hydrogenation of animal or vegetable oils having linear or branched C8-C3 2 fatty chains.
  • hydrogenated jojoba oil isomérz jojoba oil such as trans isomerized partially hydrogenated jojoba oil manufactured or marketed by Désert Whale under the trade reference ISO-JOJOBA-50 ® , hydrogenated sunflower oil, hydrogenated castor oil, marketed in particular under the name Cutina HR by Cognis, polyoxyethylenated castor oil marketed in particular under the name Cremophor EL by BASF, hydrogenated coconut oil and hydrogenated lanolin oil; preferably, the hydrogenated castor oil will be used.
  • lanolin sold in particular under the name of Medilan by Croda
  • glyceryl esters of fatty acids sold under the name of Gelucire by Gattefossé
  • hydrogenated glycerides of coconut sold under the name of name of Akosoft 36 by Karlshamns
  • the monostearate of diethylene glycol or propylene glycol sold respectively under the name Hydrine or Monosteol by Gattefosse.
  • the amount of lipophilic thickeners or gelling agents in the composition according to the invention is generally between 1 and 40% by weight relative to the total weight of the composition, preferably between 5 and 30%.
  • the composition according to the invention may contain an elastomer.
  • elastomer is understood to mean any polyorganosiloxane elastomer, namely any chemically crosslinked siloxane polymer which has viscoelastic properties such as especially and preferably the lastomer sold by Dow Corning.
  • the amount of elastomer of high molecular weight in the composition according to the invention is generally between 0% and 40%, preferably from 0 to 20% by weight relative to the total weight of the composition.
  • composition according to the invention may also comprise another surfactant, and / or at least one binder.
  • the surfactants used are preferably nonionic surfactants, used for example, but not exclusively, to facilitate the incorporation of certain constituents such as glycols into the oily phase of the composition.
  • glyceryl and optionally polyethylene glycol esters such as the mixture of glyceryl stearate and PEG-100 stearate, sold under the name Arlacel 165 by Uniqema, the mixture glyceryl stearate and PEG-75 stearate, sold under the name Gelot 64 by Gattefossé, glyceryl stearate sold under the name Cutina GMSV by Cognis; emulsifying waxes, such as the self-emulsifying wax sold under the name of Polawax NF by Croda, or the PEG-8 beeswax sold under the name of Apifil by Gattefossé; polysorbate 80 sold under the name Tween 80 by Uni
  • the composition may also comprise at least one binder.
  • binders that can be used are magnesium stearate sold by Brenntag, corn starch sold by Roquette, talc sold by WCD, cholesterol sold by Croda or silica sold by Degussa.
  • the binders can be used in an amount of between 0.1 and 30% by weight, preferably between 1 and 20% by weight.
  • composition according to the invention may also contain additives which the man of the art will choose according to the desired effect.
  • additives for example, taken alone or in combination:
  • vitamins such as vitamin PP or niacinamide
  • soothing or anti-irritant agents such as the PPG-12 / SMDI copolymer sold by the company Bertek pharmaceuticals under the trade name Polyolprepolymer-2 or else glycyrrhetinic acid or its derivatives, for example the enoxolone sold by Cognis;
  • moisturizing or humectant agents mention may be made, for example, of sugars and derivatives, of glycols, of glycerine, of sorbitol; - lecitins, cholesterol;
  • preservatives such as paraben methyl sold under the name Nipagin M by Clariant, propyl paraben sold under the name Nipasol by Clariant, or phenoxyethanol sold under the name of phenoxetol by Clariant;
  • acids or bases such as citric acid, sodium citrate, triethanolamine, aminomethylpropanol, sodium hydroxide, diisopropanolamine;
  • composition according to the invention comprises, by weight relative to the total weight:
  • composition according to the invention comprises, by weight relative to the total weight:
  • binder 0 to 30% of binder (s), 0 to 10% of additives.
  • composition according to the invention comprises, by weight relative to the total weight: 0.01 to 5% of hydroquinone or of rucinol,
  • the anhydrous composition according to the invention may be in the various known galenic forms which the person skilled in the art will adapt to the particular use of the composition.
  • compositions according to the invention are preferably formulated for topical application.
  • topical means an external application on the skin or mucous membranes.
  • compositions may be in any dosage form normally used for topical administration.
  • topical compositions mention may be made of compositions as described in the US Pharmacopoeia (USP32-NF27-Chap ⁇ 1 151> - Pharmaceutical Dosage Forms) or European Pharmacopoeia (Edition 6.3 - Chapter Semi-solid preparations for application dermal) or as defined in the decision trees of the US Food and Drug Administration (FDA) (CDER Data Standards Manual Definitions for topical dosage forms).
  • compositions according to the invention can therefore be in liquid, semi-solid, pasty or solid form and, more particularly, in the form of ointments, oily solutions, dispersions of the lotion type which may be biphasic, serum or anhydrous gels.
  • the composition is an anhydrous pharmaceutical or cosmetic composition of ointment type.
  • ointment as a semi-solid composition comprising, as a vehicle, less than 20% water and volatile compounds and more than 50% hydrocarbons, waxes, or polyols. When volatile levels are important, such compositions may be called creams (American Food and Drug Administration (FDA) decision tree).
  • FDA American Food and Drug Administration
  • the American Pharmacopoeia defines an ointment as a product whose base is a vehicle that can belong to the following 4 classes: hydrocarbon base, absorbent base, water-washable base or water-soluble base.
  • the European Pharmacopoeia defines ointment as a single-phase composition in which liquids or solids can be dispersed
  • the ointment according to the invention is a thick composition at room temperature, which comprises between 80 and 98% by weight relative to the total weight of the composition of hydrophobic compounds distinct from petroleum jelly.
  • Such compounds are in particular chosen from liquid oils alone or as a mixture, said oils possibly being volatile or nonvolatile hydrocarbons, esters, vegetable oils and / or silicone oils which can be gelled by lipophilic compounds which are solid at temperature. such as waxes, butters, esters of fatty acids.
  • a flow threshold measurement may be performed to characterize the finished product.
  • a HAAKE rheometer of type VT550 with a measurement mobile SVDIN was used.
  • the rheograms are produced at 25 ° C in the imposed speed of 0 to 100 s "1.
  • the viscosity values are given to the shear values of 4 s" 1, 20s “1 100s” 1 ( ⁇ ).
  • flow threshold ⁇ 0 expressed in Pascal
  • ⁇ 0 expressed in Pascal is meant the force required (minimum shear stress) to overcome Van der Waals cohesive forces and cause flow.
  • the composition comprises: an active phase comprising, as a pharmaceutical active agent, the phenolic derivative and at least one solvent of the phenolic derivative, an inactive phase containing at least one fatty phase thickener selected from the group consisting of behenate glyceryl and derivatives and optionally an additional lipophilic thickener, and / or at least one oil, and / or at least one lipophilic surfactant, and / or a binder, and / or any optional additive.
  • an active phase comprising, as a pharmaceutical active agent, the phenolic derivative and at least one solvent of the phenolic derivative, an inactive phase containing at least one fatty phase thickener selected from the group consisting of behenate glyceryl and derivatives and optionally an additional lipophilic thickener, and / or at least one oil, and / or at least one lipophilic surfactant, and / or a binder, and / or any optional additive.
  • the composition comprises: an active phase comprising, as a pharmaceutical active agent, the phenolic derivative and at least one solvent of the phenolic derivative, a non-active phase containing at least one phase thickener fat chosen from behenate glyceryl and derivatives and optionally an additional lipophilic thickener, and / or at least one oil, and / or at least one lipophilic surfactant, and / or a binder, and / or any optional additive, a polyorganosiloxane elastomer.
  • an active phase comprising, as a pharmaceutical active agent, the phenolic derivative and at least one solvent of the phenolic derivative, a non-active phase containing at least one phase thickener fat chosen from behenate glyceryl and derivatives and optionally an additional lipophilic thickener, and / or at least one oil, and / or at least one lipophilic surfactant, and / or a binder, and / or any optional additive, a polyorganosiloxane
  • the invention also relates to the use of the composition thus obtained as a medicament.
  • the composition can be used to prepare a medicament for the treatment and prevention of hyperpigmentary disorders such as melasma, chloasma, lentigines, senile lentigo, vitiligo, freckles, post-inflammatory hyperpigmentations.
  • hyperpigmentary disorders such as melasma, chloasma, lentigines, senile lentigo, vitiligo, freckles, post-inflammatory hyperpigmentations.
  • hyperpigmentary disorders such as melasma, chloasma, lentigines, senile lentigo, vitiligo, freckles, post-inflammatory hyperpigmentations.
  • compositions according to the invention also find application in the cosmetics field, in particular in the protection against the harmful aspects of the sun, for preventing and / or for combating photoinduced or chronological aging of the skin and superficial body growths.
  • the invention also relates to a non-therapeutic cosmetic treatment method for beautifying the skin and / or improving its surface appearance, characterized in that a composition comprising at least one depigmenting agent is applied to the skin and / or its integuments.
  • anhydrous compositions according to the invention are obtained by those skilled in the art using a conventional and known method of mixing the phases.
  • the manufacturing process may include the following steps:
  • the preferred solvents are Crodamol DA, Arlamol E and Labrasol, which give hydroquinone good chemical and physical stability (macroscopic observation of the color), coupled with a good solubilizing effect.
  • the use of such solvents may therefore make it possible to dispense with any use of antioxidants.
  • Cremophor may be used in limited amounts to assist in the solubilization of hydroquinone, but preferably alongside a hydroquinone stabilizing solvent, such as medium chain triglycerides such as Miglyol ® 218N.
  • phase E While maintaining stirring, homogenize for about 5 minutes.
  • PHASE A In the form beaker, solubilize the hydroquinone in the solvent (PPG-15 Stearyl Ether) with magnetic stirring by heating at 75 ° C. Stop heating and maintain agitation.
  • PHASE B In an auxiliary beaker, weigh caprylic capric triglycerides.
  • phase B into phase A with magnetic stirring. Then, add the silicone or Cetiol SN PH in the mixture obtained previously. Leave stirring until homogenization.
  • Phase C In an auxiliary beaker, solubilize hydroquinone in PPG-15 Stearyl ether with magnetic stirring by heating to about 75 ° C. Phase C:
  • Phase B In an auxiliary beaker, weigh caprylic capric triglycerides.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
EP09769518A 2008-05-30 2009-06-02 Nouvelles compositions dépigmentantes anhydre comprenant un dérivé phénolique solubilisé Withdrawn EP2291179A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0853578A FR2931663B1 (fr) 2008-05-30 2008-05-30 Nouvelles compositions depigmentantes anhydre comprenant un derive phenolique solubilise.
PCT/FR2009/051038 WO2009156677A2 (fr) 2008-05-30 2009-06-02 Nouvelles compositions dépigmentantes anhydre comprenant un dérivé phénolique solubilisé

Publications (1)

Publication Number Publication Date
EP2291179A2 true EP2291179A2 (fr) 2011-03-09

Family

ID=39722652

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09769518A Withdrawn EP2291179A2 (fr) 2008-05-30 2009-06-02 Nouvelles compositions dépigmentantes anhydre comprenant un dérivé phénolique solubilisé

Country Status (12)

Country Link
US (1) US20110144213A1 (ja)
EP (1) EP2291179A2 (ja)
JP (1) JP2011521935A (ja)
KR (1) KR20110026440A (ja)
CN (1) CN102046160A (ja)
AU (1) AU2009264013A1 (ja)
BR (1) BRPI0907661A2 (ja)
CA (1) CA2723342A1 (ja)
FR (1) FR2931663B1 (ja)
MX (1) MX2010012755A (ja)
RU (1) RU2010153984A (ja)
WO (1) WO2009156677A2 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2946250A1 (fr) * 2009-06-05 2010-12-10 Galderma Res & Dev Compositions topiques depigmentantes, et leurs utilisations.
FR2946249B1 (fr) * 2009-06-05 2012-07-06 Galderma Res & Dev Compositions topiques depigmentantes, et leurs utilisations.
CA2940494C (en) 2014-03-14 2022-11-08 Gojo Industries, Inc. Hand sanitizers with improved aesthetics and skin-conditioning to encourage compliance with hand hygiene guidelines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4466955A (en) * 1982-06-09 1984-08-21 Germaine Monteil Cosmetiques Corporation Skin bleaching stick containing hydroquinone
US4678663A (en) * 1984-02-06 1987-07-07 Nuetrogena Corporation Hydroquinone composition having enhanced bio-availability and percutaneous adsorption
US6110449A (en) * 1999-06-14 2000-08-29 The Procter & Gamble Company Anhydrous antiperspirant cream compositions improved perfume longevity
JP2006508900A (ja) * 2002-06-25 2006-03-16 ディーエスエム アイピー アセッツ ビー．ブイ． ベンゾオキサゾールおよびベンゾジアゾールｕｖ−ａサンスクリーン
KR20050057238A (ko) * 2002-09-05 2005-06-16 갈데르마 리써어치 앤드 디벨로프먼트,에스.엔.씨. 아다팔렌 및 하나 이상의 탈색소제를 함유한 피부용 탈색소조성물
DE102004003478A1 (de) * 2004-01-22 2005-08-18 Basf Ag Retinoid-haltige Zubereitungen
US20060120979A1 (en) * 2004-12-02 2006-06-08 Joel Rubin Skin care composition comprising hydroquinone and a substantially anhydrous base
ES2272164B1 (es) * 2005-06-03 2008-04-01 Isdin, S.A. Nuevos derivados de pirroliltriazina asi como procedimientos para su obtencion y su utilizacion como agentes protectores contra la radiacionuv.
FR2894141A1 (fr) * 2005-12-06 2007-06-08 Galderma Res & Dev Composition depigmentante de la peau compreant un derive d'acide naphtoique
FR2909284B1 (fr) * 2006-11-30 2012-09-21 Galderma Sa Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien
FR2915682B1 (fr) * 2007-05-04 2009-07-03 Galderma Res & Dev Compositions depigmentantes dermatologiques et cosmetiques, leurs procedes de preparation, et leurs utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009156677A2 *

Also Published As

Publication number Publication date
BRPI0907661A2 (pt) 2015-07-21
RU2010153984A (ru) 2012-07-10
FR2931663B1 (fr) 2010-07-30
WO2009156677A2 (fr) 2009-12-30
KR20110026440A (ko) 2011-03-15
MX2010012755A (es) 2010-12-21
WO2009156677A3 (fr) 2010-02-25
CA2723342A1 (fr) 2009-12-30
AU2009264013A1 (en) 2009-12-30
CN102046160A (zh) 2011-05-04
JP2011521935A (ja) 2011-07-28
FR2931663A1 (fr) 2009-12-04
US20110144213A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
EP1758588B1 (fr) Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises.
FR2909000A1 (fr) Compositions comprenant du peroxyde de benzoyle, au moins un derive de l'acide naphtoique et au moins un compose de type polymeres de polyurethane ou des derives de celui-ci, et leurs utilisations.
FR2901139A1 (fr) Compositions comprenant au moins un derive de l'acide naphtoique et du peroxyde de benzoyle, leurs procedes de preparation, et leurs utilisations
WO2006003299A1 (fr) Gel dépigmentant hydroalcoolique comprenant du méquinol et de l'adapalène
WO2009156675A2 (fr) Nouvelles compositions dépigmentantes sous forme d'une composition anhydre sans vaseline et sans élastomère comprenant un dérivé phénolique solubilisé et un rétinoïde
WO2009156679A1 (fr) Compositions depigmentantes anhydres comprenant, au sein de la phase grasse un derive phenolique solubilise et un retinoide
WO2009156676A1 (fr) Nouvelles compositions dépigmentantes sous forme d'une composition anhydre sans vaseline et sans élastomère comprenant un dérivé phénolique solubilisé
EP2291179A2 (fr) Nouvelles compositions dépigmentantes anhydre comprenant un dérivé phénolique solubilisé
FR2894474A1 (fr) Gel depigmentant hydroalcoolique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101230

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130430

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130911